Benicar Sales Aid Draws FDA Warning Letter
This article was originally published in The Pink Sheet Daily
Agency objects to superiority and efficacy claims for the Forest/Sankyo angiotension II receptor blocker based on misleading comparisons and inadequate studies.
You may also be interested in...
The impact of media attention on the adult suicide issue will be “hard to predict,” President & COO Goodman says. Forest expects FDA action on a Namenda supplemental NDA for mild-to-moderate Alzheimer’s in the next few weeks.
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.